Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance (original) (raw)

Change history

In the version of this article initially published online, the middle initial of collaborator Maarten R. Soeters was inadvertently omitted. The error has been corrected for the print, PDF and HTML versions of this article.

References

  1. Samuel, V.T. & Shulman, G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12–22 (2016).
    Article PubMed PubMed Central Google Scholar
  2. Ginsberg, H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453–458 (2000).
    Article CAS PubMed PubMed Central Google Scholar
  3. Shulman, G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 1131–1141 (2014).
    Article PubMed CAS Google Scholar
  4. Lillioja, S. & Bogardus, C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab. Rev. 4, 517–540 (1988).
    Article CAS PubMed Google Scholar
  5. Perry, R.J., Samuel, V.T., Petersen, K.F. & Shulman, G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91 (2014).
    Article CAS PubMed PubMed Central Google Scholar
  6. Arner, P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137–145 (2003).
    Article CAS PubMed Google Scholar
  7. Friedman, J.M. Obesity in the new millennium. Nature 404, 632–634 (2000).
    Article CAS PubMed Google Scholar
  8. Guilherme, A., Virbasius, J.V., Puri, V. & Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 367–377 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  9. Friedman, J.M. A war on obesity, not the obese. Science 299, 856–858 (2003).
    Article CAS PubMed Google Scholar
  10. Hardy, O.T., Czech, M.P. & Corvera, S. What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81–87 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  11. Stefan, N., Häring, H.U., Hu, F.B. & Schulze, M.B. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 1, 152–162 (2013).
    Article PubMed Google Scholar
  12. Robbins, A.L. & Savage, D.B. The genetics of lipid storage and human lipodystrophies. Trends Mol. Med. 21, 433–438 (2015).
    Article CAS PubMed Google Scholar
  13. Semple, R.K., Savage, D.B., Cochran, E.K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 32, 498–514 (2011).
    Article CAS PubMed Google Scholar
  14. Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  15. Danforth, E. Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat. Genet. 26, 13 (2000).
    Article CAS PubMed Google Scholar
  16. Unger, R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14, 398–403 (2003).
    Article CAS PubMed Google Scholar
  17. Virtue, S. & Vidal-Puig, A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—an allostatic perspective. Biochim. Biophys. Acta 1801, 338–349 (2010).
    Article CAS PubMed Google Scholar
  18. Shulman, G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171–176 (2000).
    Article CAS PubMed PubMed Central Google Scholar
  19. Karpe, F. & Pinnick, K.E. Biology of upper-body and lower-body adipose tissue—link to whole-body phenotypes. Nat. Rev. Endocrinol. 11, 90–100 (2015).
    Article CAS PubMed Google Scholar
  20. Robbins, D.C. et al. The effect of diet on thermogenesis in acquired lipodystrophy. Metabolism 28, 908–916 (1979).
    Article CAS PubMed Google Scholar
  21. Shimomura, I., Hammer, R.E., Ikemoto, S., Brown, M.S. & Goldstein, J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73–76 (1999).
    Article CAS PubMed Google Scholar
  22. Oral, E.A. et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578 (2002).
    Article CAS PubMed Google Scholar
  23. Gavrilova, O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271–278 (2000).
    Article CAS PubMed PubMed Central Google Scholar
  24. Kim, J.Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621–2637 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  25. Gray, S.L. et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice. Diabetes 55, 2669–2677 (2006).
    Article CAS PubMed Google Scholar
  26. Medina-Gomez, G. et al. PPARγ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64 (2007).
    Article PubMed PubMed Central CAS Google Scholar
  27. Knowles, J.W. et al. Identification and validation of _N_-acetyltransferase 2 as an insulin sensitivity gene. J. Clin. Invest. 126, 403 (2016).
    Article PubMed PubMed Central Google Scholar
  28. Scott, R.A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991–1005 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  29. Manning, A.K. et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat. Genet. 44, 659–669 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  30. Salazar, M.R. et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab. Vasc. Dis. Res. 10, 346–352 (2013).
    Article PubMed CAS Google Scholar
  31. Scott, R.A. et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes 63, 4378–4387 (2014).
    Article CAS PubMed Google Scholar
  32. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).
  33. Prokopenko, I. et al. A central role for GRB10 in regulation of islet function in man. PLoS Genet. 10, e1004235 (2014).
    Article PubMed PubMed Central CAS Google Scholar
  34. Morris, A.P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981–990 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  35. Nikpay, M. et al. A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47, 1121–1130 (2015).
    Article CAS PubMed PubMed Central Google Scholar
  36. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196 (2015).
    Article CAS PubMed PubMed Central Google Scholar
  37. Kozaki, K. et al. Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J. Lipid Res. 34, 1765–1772 (1993).
    CAS PubMed Google Scholar
  38. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N. Engl. J. Med. 374, 1134–1144 (2016).
  39. Mailly, F. et al. A common variant in the gene for lipoprotein lipase (Asp9→Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 15, 468–478 (1995).
    Article CAS PubMed Google Scholar
  40. Avila, M. et al. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: towards recommendation for molecular testing and management. Clin. Genet. http://dx.doi.org/10.1111/cge.12688 (2015).
  41. Thauvin-Robinet, C. et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am. J. Hum. Genet. 93, 141–149 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  42. Chudasama, K.K. et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 93, 150–157 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  43. Dyment, D.A. et al. Mutations in PIK3R1 cause SHORT syndrome. Am. J. Hum. Genet. 93, 158–166 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  44. Pers, T.H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat. Commun. 6, 5890 (2015).
    Article CAS PubMed Google Scholar
  45. Lane, J.M., Doyle, J.R., Fortin, J.P., Kopin, A.S. & Ordovás, J.M. Development of an OP9 derived cell line as a robust model to rapidly study adipocyte differentiation. PLoS One 9, e112123 (2014).
    Article PubMed PubMed Central CAS Google Scholar
  46. Yaghootkar, H. et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63, 4369–4377 (2014).
    Article CAS PubMed PubMed Central Google Scholar
  47. Lu, Y. et al. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. Nat. Commun. 7, 10495 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  48. Kilpeläinen, T.O. et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat. Genet. 43, 753–760 (2011).
    Article PubMed PubMed Central CAS Google Scholar
  49. Yaghootkar, H. et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease. Diabetes 65, 2448–2460 (2016).
    Article CAS PubMed Google Scholar
  50. Biggs, M.L. et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. J. Am. Med. Assoc. 303, 2504–2512 (2010).
    Article CAS Google Scholar
  51. Pischon, T. et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359, 2105–2120 (2008).
    Article CAS PubMed Google Scholar
  52. Vague, J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr. 4, 20–34 (1956).
    Article CAS PubMed Google Scholar
  53. Smith, U. Abdominal obesity: a marker of ectopic fat accumulation. J. Clin. Invest. 125, 1790–1792 (2015).
    Article PubMed PubMed Central Google Scholar
  54. Després, J.P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881–887 (2006).
    Article PubMed CAS Google Scholar
  55. Dahlman, I. et al. Numerous genes in loci associated with body fat distribution are linked to adipose function. Diabetes 65, 433–437 (2016).
    Article CAS PubMed Google Scholar
  56. Rydén, M., Andersson, D.P., Bergström, I.B. & Arner, P. Adipose tissue and metabolic alterations: regional differences in fat cell size and number matter, but differently: a cross-sectional study. J. Clin. Endocrinol. Metab. 99, E1870–E1876 (2014).
    Article PubMed CAS Google Scholar
  57. Pinnick, K.E. et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63, 3785–3797 (2014).
    Article CAS PubMed Google Scholar
  58. Baughman, B.M., Pattenden, S.G., Norris, J.L., James, L.I. & Frye, S.V. The L3MBTL3 methyl-lysine reader domain functions as a dimer. ACS Chem. Biol. 11, 722–728 (2016).
    Article CAS PubMed Google Scholar
  59. Randall, J.C. et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet. 9, e1003500 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  60. Paternoster, L. et al. Adult height variants affect birth length and growth rate in children. Hum. Mol. Genet. 20, 4069–4075 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  61. Wood, A.R. et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet. 46, 1173–1186 (2014).
    Article CAS PubMed PubMed Central Google Scholar
  62. Gupta, G.D. et al. A dynamic protein interaction landscape of the human centrosome–cilium interface. Cell 163, 1484–1499 (2015).
    Article CAS PubMed PubMed Central Google Scholar
  63. Singaraja, R.R. et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. J. Lipid Res. 55, 1693–1701 (2014).
    Article CAS PubMed PubMed Central Google Scholar
  64. Chasman, D.I. et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5, e1000730 (2009).
    Article PubMed PubMed Central CAS Google Scholar
  65. DeFronzo, R.A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104–1115 (2011).
    Article CAS PubMed Google Scholar
  66. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096–1105 (2006).
  67. Lincoff, A.M., Wolski, K., Nicholls, S.J. & Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J. Am. Med. Assoc. 298, 1180–1188 (2007).
    Article CAS Google Scholar
  68. Kernan, W.N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  69. Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457–2471 (2007).
    Article CAS PubMed Google Scholar
  70. Food and Drug Administration. Guidance for Industry. Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (Food and Drug Administration, 2008).
  71. Swerdlow, D.I. et al. HMG–coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385, 351–361 (2015).
    Article CAS PubMed PubMed Central Google Scholar
  72. Dewey, F.E. et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123–1133 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  73. Do, R. et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102–106 (2015).
    Article CAS PubMed Google Scholar
  74. Jørgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).
    Article PubMed CAS Google Scholar
  75. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22–31 (2014).
  76. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371, 2072–2082 (2014).
  77. Moltke, I. et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512, 190–193 (2014).
    Article CAS PubMed Google Scholar
  78. Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br. J. Cancer 80 (Suppl. 1), 95–103 (1999).
    PubMed Google Scholar
  79. Riboli, E. et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 5, 1113–1124 (2002).
    Article CAS PubMed Google Scholar
  80. InterAct Consortium. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 54, 2272–2282 (2011).
  81. Collins, R. What makes UK Biobank special? Lancet 379, 1173–1174 (2012).
    Article PubMed Google Scholar
  82. Lyssenko, V. et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 117, 2155–2163 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  83. Aschard, H., Vilhjálmsson, B.J., Joshi, A.D., Price, A.L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am. J. Hum. Genet. 96, 329–339 (2015).
    Article CAS PubMed PubMed Central Google Scholar
  84. Day, F.R., Loh, P.R., Scott, R.A., Ong, K.K. & Perry, J.R. A robust example of collider bias in a genetic association study. Am. J. Hum. Genet. 98, 392–393 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  85. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658–665 (2013).
    Article PubMed PubMed Central Google Scholar
  86. Lawrence, R.D. Types of human diabetes. BMJ 1, 373–375 (1951).
    Article CAS PubMed PubMed Central Google Scholar
  87. Herbst, K.L. et al. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 26, 1819–1824 (2003).
    Article PubMed Google Scholar
  88. Payne, F. et al. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance. J. Clin. Invest. 124, 4028–4038 (2014).
    Article CAS PubMed PubMed Central Google Scholar
  89. UK10K Consortium. The UK10K project identifies rare variants in health and disease. Nature 526, 82–90 (2015).
  90. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  91. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2011).
    Article PubMed CAS Google Scholar
  92. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
    Article CAS PubMed Google Scholar
  93. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336–2337 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  94. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930–D934 (2012).
    Article CAS PubMed Google Scholar
  95. Johnson, A.D. et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938–2939 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  96. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP–trait associations. Nucleic Acids Res. 42, D1001–D1006 (2014).
    Article CAS PubMed Google Scholar
  97. Zhang, X. et al. Synthesis of 53 tissue and cell line expression QTL datasets reveals master eQTLs. BMC Genomics 15, 532 (2014).
    Article PubMed PubMed Central CAS Google Scholar
  98. Buil, A. et al. Gene–gene and gene–environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet. 47, 88–91 (2015).
    Article CAS PubMed Google Scholar
  99. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
  100. Nica, A.C. et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 6, e1000895 (2010).
    Article PubMed PubMed Central CAS Google Scholar

Download references

Acknowledgements

We are grateful for the OP9-K cells kindly shared by the laboratory of A. Kopin (Tufts Medical Center). The authors gratefully acknowledge the help of the MRC Epidemiology Unit Support Teams, including the Field Teams, the Laboratory Team and the Data Management Team, and of the staff of the Wellcome Trust Clinical Research Facility.

This study was funded by the UK Medical Research Council through grants MC_UU_12015/1, MC_PC_13046, MC_PC_13048 and MR/L00002/1. This work was supported by the MRC Metabolic Diseases Unit (MC_UU_12012/5) and the Cambridge NIHR Biomedical Research Centre and EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant 115372). Funding for the InterAct project was provided by the EU FP6 program (grant LSHM_CT_2006_037197). This work was funded, in part, through an EFSD Rising Star award to R.A.S. supported by Novo Nordisk. D.B.S. is supported by Wellcome Trust grant 107064. M.I.M. is a Wellcome Trust Senior Investigator and is supported by the following grants from the Wellcome Trust: 090532 and 098381. M.v.d.B. is supported by a Novo Nordisk postdoctoral fellowship run in partnership with the University of Oxford. I.B. is supported by Wellcome Trust grant WT098051. S.O'R. acknowledges funding from the Wellcome Trust (Wellcome Trust Senior Investigator Award 095515/Z/11/Z and Wellcome Trust Strategic Award 100574/Z/12/Z).

AUTHOR CONTRUBUTIONS

Concept and design: L.A.L., I.B., N.J.W., D.B.S., C.L., S.O'R. and R.A.S. Generation, acquisition, analysis and/or interpretation of data: all authors. Drafting of the manuscript: L.A.L., I.B., N.J.W., D.B.S., C.L., S.O'R. and R.A.S. Critical review of the manuscript for important intellectual content and approval of the final version of the manuscript: all authors.

Author information

Author notes

  1. Nicholas J Wareham, Richard Ross, Stephen O'Rahilly, David B Savage, Inês Barroso, Nicholas J Wareham, David B Savage, Claudia Langenberg, Stephen O'Rahilly and Robert A Scott: These authors contributed equally to this work

Authors and Affiliations

  1. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
    Luca A Lotta, Felix R Day, Stephen J Sharp, Jian'an Luan, Emanuella De Lucia Rolfe, Isobel D Stewart, Sara M Willems, Claudia Langenberg, Robert A Scott, Stephen J Sharp, Nita G Forouhi, Nicola D Kerrison, Matt Sims, Debora M E Lucarelli, Nicholas J Wareham, Nita G Forouhi, John R B Perry, Nicholas J Wareham, Claudia Langenberg & Robert A Scott
  2. Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
    Pawan Gulati, Claire Adams, Inês Barroso, Panos Deloukas, Robert K Semple, Claire Adams, Stephen O'Rahilly, David B Savage, Robert K Semple, Inês Barroso, David B Savage & Stephen O'Rahilly
  3. Wellcome Trust Sanger Institute, Hinxton, UK
    Felicity Payne, Eleanor Wheeler, Inês Barroso & Inês Barroso
  4. Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
    Halit Ongen & Emmanouil Dermitzakis
  5. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Martijn van de Bunt, Mark I McCarthy & Mark I McCarthy
  6. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Martijn van de Bunt, Mark I McCarthy & Mark I McCarthy
  7. Department of Pediatrics, University of California at San Diego, La Jolla, California, USA
    Kyle J Gaulton
  8. Division of Intramural Research, Population Sciences Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    John D Eicher & Andrew D Johnson
  9. Genetics of Complex Traits, Institute of Biomedical and Clinical Science, University of Exeter Medical School, Royal Devon and Exeter Hospital, Exeter, UK
    Hanieh Yaghootkar & Timothy Frayling
  10. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Kay-Tee Khaw
  11. Public Health Division of Gipuzkoa, San Sebastian, Spain
    Larraitz Arriola
  12. Instituto BIO-Donostia, Basque Government, San Sebastian, Spain
    Larraitz Arriola
  13. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
    Larraitz Arriola, Aurelio Barricarte, Carmen Navarro & Elena Salamanca-Fernández
  14. INSERM, CESP, U1018, Villejuif, France
    Beverley Balkau
  15. Université Paris–Sud, UMRS 1018, Villejuif, France
    Beverley Balkau
  16. Navarre Public Health Institute (ISPN), Pamplona, Spain
    Aurelio Barricarte
  17. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
    Aurelio Barricarte
  18. German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
    Heiner Boeing
  19. Lund University, Malmö, Sweden
    Paul W Franks
  20. Umeå University, Umeå, Sweden
    Paul W Franks & Olov Rolandsson
  21. Catalan Institute of Oncology (ICO), Barcelona, Spain
    Carlos Gonzalez
  22. Epidemiology and Prevention Unit, Milan, Italy
    Sara Grioni
  23. German Cancer Research Centre (DKFZ), Heidelberg, Germany
    Rudolf Kaaks
  24. Nuffield Department of Population Health, University of Oxford, Oxford, UK
    Timothy J Key
  25. Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
    Carmen Navarro
  26. Unit of Preventive Medicine and Public Health, School of Medicine, University of Murcia, Murcia, Spain
    Carmen Navarro
  27. Department of Clinical Sciences, Lund University, Skane University Hospital, Malmö, Sweden
    Peter M Nilsson
  28. Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
    Kim Overvad
  29. Aalborg University Hospital, Aalborg, Denmark
    Kim Overvad
  30. Cancer Research and Prevention Institute (ISPO), Florence, Italy
    Domenico Palli
  31. Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
    Salvatore Panico
  32. Public Health Directorate, Oviedo, Spain
    J Ramón Quirós
  33. Unit of Cancer Epidemiology, Città della Salute e della Scienza Hospital, University of Turin, and Center for Cancer Prevention (CPO), Turin, Italy
    Carlotta Sacerdote
  34. Human Genetics Foundation (HuGeF), Turin, Italy
    Carlotta Sacerdote
  35. Andalusian School of Public Health, Granada, Spain
    Elena Salamanca-Fernández
  36. Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada, Spain
    Elena Salamanca-Fernández
  37. International Agency for Research on Cancer, Lyon, France
    Nadia Slimani
  38. Danish Cancer Society Research Center, Copenhagen, Denmark
    Anne Tjonneland
  39. ASP Ragusa, Ragusa, Italy
    Rosario Tumino
  40. National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
    Annemieke M W Spijkerman & Daphne L van der A
  41. University Medical Center Utrecht, Utrecht, the Netherlands
    Yvonne T van der Schouw
  42. School of Public Health, Imperial College London, London, UK
    Elio Riboli
  43. Wolfson Diabetes and Endocrine Clinic, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    Anna Stears, Ellie Gurnell & Amanda Adler
  44. East and North Herts NHS Trust, Lister Hospital, Herts, UK
    Stella George
  45. Institute of Cellular Medicine (Diabetes), Newcastle University Medical School, Newcastle-upon-Tyne, UK
    Mark Walker
  46. Harrogate and District Hospital, Harrogate, UK
    Deirdre Maguire
  47. James Cook University Hospital, Middlesborough, UK
    Rasha Mukhtar & Sath Nag
  48. Department of Endocrinology and Metabolism, Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands
    Maarten R Soeters
  49. St Richard's Hopsital, Chichester, UK
    Ken Laji
  50. North Devon District Hospital, Raleigh Park, Barnstaple, UK
    Alistair Watt
  51. King's College Hospital, London, UK
    Simon Aylwin
  52. Department of Diabetes and Endocrinology, Southmead Hospital, Bristol, UK
    Andrew Johnson
  53. Ipswich Hospital, Ipswich, UK
    Gerry Rayman
  54. University Hospital of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, UK
    Fahmy Hanna
  55. Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
    Sian Ellard
  56. Medical School, University of Sheffield, Sheffield, UK
    Richard Ross
  57. Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Zagreb, Croatia
    Kristina Blaslov & Lea Smirčić Duvnjak

Authors

  1. Luca A Lotta
  2. Pawan Gulati
  3. Felix R Day
  4. Felicity Payne
  5. Halit Ongen
  6. Martijn van de Bunt
  7. Kyle J Gaulton
  8. John D Eicher
  9. Stephen J Sharp
  10. Jian'an Luan
  11. Emanuella De Lucia Rolfe
  12. Isobel D Stewart
  13. Eleanor Wheeler
  14. Sara M Willems
  15. Claire Adams
  16. Hanieh Yaghootkar
  17. Nita G Forouhi
  18. Kay-Tee Khaw
  19. Andrew D Johnson
  20. Robert K Semple
  21. Timothy Frayling
  22. John R B Perry
  23. Emmanouil Dermitzakis
  24. Mark I McCarthy
  25. Inês Barroso
  26. Nicholas J Wareham
  27. David B Savage
  28. Claudia Langenberg
  29. Stephen O'Rahilly
  30. Robert A Scott

Consortia

EPIC-InterAct Consortium

Cambridge FPLD1 Consortium

Corresponding authors

Correspondence toInês Barroso, Nicholas J Wareham, David B Savage, Claudia Langenberg, Stephen O'Rahilly or Robert A Scott.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Design and scope of the study.

Supplementary Figure 2 Design of the study, investigated phenotypes, sources of data and sample size.

The reported sample size is the maximum available for a given trait or set of traits in this study. *In the study by Knowles and colleagues (PubMed ID: 25798622), insulin sensitivity was measured by euglycemic clamp or insulin suppression test in 2,764 European individuals from four cohorts. IR, insulin resistance; FIadjBMI, fasting insulin levels adjusted for body mass index; TG, triglyceride levels; HDL, high-density lipoprotein cholesterol levels; ISI, insulin sensitivity index; DEXA, dual-energy X-ray absorptiometry; BF%, body fat percentage; FPLD1, familial partial lipodystrophy type 1; MAGIC, Meta-Analyses of Glucose- and Insulin-related traits Consortium; GLGC, Global Lipids Genetics Consortium; GIANT, Genetic Investigation of ANthropometric Traits; DIAGRAM, DIAbetes Genetics Replication And Meta-analysis; CARDIOGRAM, Coronary ARtery DIsease Genome-wide Replication and Meta-analysis; C4D, Coronary Artery Disease Genetics consortium.

(a–c) Manhattan plots of the association of SNPs with fasting insulin adjusted for body mass index (FIadjBMI) (a), triglycerides (b) and HDL cholesterol (c). We plotted only variants with FIadjBMI, triglycerides and HDL cholesterol (P < 0.005 for each phenotype). All associations are represented for the FIadjBMI-raising allele. The 630 alleles associated with higher FIadjBMI, higher triglycerides and lower HDL cholesterol are plotted in dark red. The graph also plots 21 variants that met the _P_-value threshold for the three phenotypes but were not associated in the required direction (gray). For graphic display purposes, P values below 10−20 are represented as 10−20.

Supplementary Figure 4 Flowchart of the identification of insulin resistance loci.

Numbers refer to SNPs. FIadjBMI, fasting insulin adjusted for body mass index; HDL, high-density lipoprotein cholesterol; TG, triglycerides.

Supplementary Figure 5 Associations with insulin resistance phenotypes in an independent data set.

The figure reports associations of the genetic scores comprising the 53 or 43 SNPs with fasting insulin adjusted for body mass index, triglycerides and HDL cholesterol in up to 6,101 participants of the Fenland study who were not included in any of the discovery efforts used for identification of the 53 loci. Squares indicate the central estimate of the β coefficient; error bars represent 95% confidence intervals. N, number of participants; FIadjBMI, fasting insulin adjusted for body mass index; HDL, high-density lipoprotein; SD, standard deviation.

Supplementary Figure 6 Associations with glycemic and anthropometric traits and with disease endpoints at the 53 genomic loci.

The heat map represents z scores for the association of the lead insulin-raising allele at each locus. Loci are ranked on the basis of their z scores for fasting insulin (largest to smallest). With the exception of fasting insulin, none of the association analyses were adjusted for body mass index. N, maximum sample size; FIadjBMI, fasting insulin adjusted for body mass index; HDL, high-density lipoprotein cholesterol; BMI, body mass index; WHR, waist–hip ratio; CHD, coronary heart disease; T2D, type 2 diabetes. Color scale: red indicates positive associations for the insulin-raising allele at each locus, while blue indicates negative associations. Asterisks indicate known loci for the traits, i.e., those for which our lead SNP is within 500 kb on either side of a lead SNP from the largest GWAS for that trait.

Supplementary Figure 7 Associations of the genetic scores comprising the 53 or 43 SNPs with glycemic and anthropometric traits in large-scale meta-analyses and in the Fenland study.

(a) Association of the genetic scores with anthropometric and glycemic traits in meta-analyses of genetic association studies. Body mass index, waist–hip ratio, and waist and hip circumference data are from the GIANT consortium and the UK Biobank study. Body fat percentage data are from the UK Biobank, EPIC-Norfolk and Fenland studies. Fasting plasma glucose, 2-h glucose and HbA1c data are from the MAGIC consortium. Leg fat mass data are from the EPIC-Norfolk and Fenland studies. Squares with error bars represent the per-allele β coefficients in standard deviation units and their 95% confidence intervals. (b) Association with the same traits in participants of the Fenland study not included in the discovery efforts that contributed to the identification of the 53 loci. Because HbA1c has been measured only in a subset of Fenland participants, the HbA1c analysis also includes individuals from the InterAct study subcohort who did not take part in the discovery efforts that contributed to the identification of the 53 loci. Squares with error bars represent the per-allele β coefficients in standard deviation units and their 95% confidence intervals. Red and blue squares represent the results of the 53-SNP and 43-SNP genetic scores, respectively. None of the results presented in the figure were adjusted for body mass index. N, number of participants; SD, standard deviation; BMI, body mass index; WHR, waist–hip ratio; FPG, fasting plasma glucose.

Supplementary Figure 8 Associations of the 53-SNP genetic score with detailed anthropometric variables from dual-energy X-ray absorptiometry.

The figure represents the association of quintiles of the 53-SNP genetic score with the absolute values of compartmental and total fat mass. Data are from 9,747 participants of the Fenland study. The Fenland population was divided into quintiles of the distribution of the genetic score, and each quintile was compared with the bottom (reference category). Squares with error bars represent the β coefficients in grams for individuals in the exposure category as compared with the reference category and their 95% confidence intervals.

Supplementary Figure 9 Associations of the rs4976033[G] allele near PIK3R1 with continuous metabolic traits and cardiometabolic disease endpoints.

(a) Associations with continuous traits. (b) Associations with disease endpoints. Squares with error bars represent the β coefficients (a) or odds ratios (b) and their 95% confidence intervals. HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; WHR, waist–hip ratio; FIadjBMI, fasting insulin adjusted for BMI; FPG, fasting plasma glucose; 2hr glucose, glucose at 2 h during an oral glucose challenge; SD, standard deviation; OR, odds ratio.

Supplementary Figure 10 Associations of functional variants in LPL with cardiometabolic traits and disease endpoints.

(a) Association of the gain-of-function p.Ser447* (rs328; left) and the loss-of-function p.Asp36Asn (rs1801177; right) variants in LPL with lipid levels, anthropometric traits, liver markers and glycemic traits. (b) Association of the two variants with the risk of coronary heart disease (from the Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators; PubMed ID: 26934567) and that of type 2 diabetes. Squares with error bars represent the β coefficients (a) or odds ratios (b) and their 95% confidence intervals. HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; WHR, waist–hip ratio; VAT, visceral adipose tissue; ALT, alanine aminotransferase; GGT, γ-glutamyltransferase; FIadjBMI, fasting insulin adjusted for BMI; FPG, fasting plasma glucose; 2hr, glucose at 2 h during an oral glucose challenge; SD, standard deviation; OR, odds ratio.

Supplementary Figure 11 Mechanistic hypothesis for the implication of putative effector genes in the observed associations and selection of genes for experimental validation in cellular models of adipogenesis.

(a) Mechanistic hypothesis. (b) Selection criteria to prioritize genes for experimental validation. (c) Selection flowchart. Numbers in c refer to loci meeting certain selection criteria. *We did not take forward the KLF14 gene to experimental validation because previous studies on the role of this gene in metabolic disease suggest complex etiological mechanisms at this locus, including a possible parent-of-origin effect.

Supplementary Figure 12 Associations with fasting insulin adjusted for body mass index, body mass index or fasting insulin of the 53 polymorphisms identified in this study.

(a) Association of the 53 lead polymorphisms from our study with FIadjBMI as a function of the association with BMI. There was no clear bias in the association with FIadjBMI (linear regression between the β coefficients of the 53 polymorphisms, P = 0.26). (b) Association with FI (unadjusted for BMI) of the lead 53 polymorphisms as a function of the association with FIadjBMI. The line of fit was aligned with the line of equality consistent with no bias. In a, the dark red line and surrounding areas represent the line of fit with 95% confidence areas. The dashed gray line in b represents the line of equality. Data on fasting insulin associations are from the MAGIC consortium; data on BMI associations are from the GIANT consortium.

Supplementary Figure 13 Scatterplot matrix of the top ten genetic principal components in women with FPLD1 and control women from UKHLS.

Supplementary information

Rights and permissions

About this article

Cite this article

Lotta, L., Gulati, P., Day, F. et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance.Nat Genet 49, 17–26 (2017). https://doi.org/10.1038/ng.3714

Download citation